Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Freya Meds vs OlleveCare

Freya Meds
Graded #364

Higher grade

vs+12.399999999999999
OlleveCare
Graded #497

Lower grade

The verdict

Freya Meds takes it — 58.6/100 to 46.2/100.

Freya Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Freya Meds is a GLP-1 specialist offering compounded semaglutide ($250–$297/mo) and compounded tirzepatide ($332–$390/mo).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueOlleveCare +2
43
45
Dose & formulationFreya Meds +24
64
40
Clinical oversightFreya Meds +18
71
53
Labs & monitoringFreya Meds +11
60
49
FulfillmentFreya Meds +24
62
38
Contract termsEven
55
55
Freya Meds · left barOlleveCare · right bar

The numbers

MetricFreya MedsOlleveCare
WeighScore58.6/10046.2/100
GradeCC
Scorecard rank#364#497
Semaglutide$297/mo (compounded)Not disclosed
Tirzepatide$390/mo (compounded)Not disclosed
CoverageCoverage not published13 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Freya Meds

Graded #364 · C

Strengths

  • GLP-1 specialist — not a multi-category telehealth
  • Price includes unlimited doctor consultations, monthly group calls, and a dietitian consultation
  • Both semaglutide and tirzepatide available
  • Multi-month discount on quarterly billing
  • Claims 450,000+ enrolled

Where it loses points

  • No visible LegitScript or PCAB accreditation
  • Above-average pricing ($250–$390/mo)
  • Compounded only — no brand-name options
  • Now serves 49 U.S. states (one state excluded; specific exclusion not named)
OlleveCare

Graded #497 · C

Strengths

  • 13 states listed explicitly (VA, FL, AZ, MA, HI, IA, MD, NM, WA, KS, NY, DC, ID)
  • Both semaglutide and tirzepatide offered — switch molecules without switching platforms
  • Multi-service platform — GLP-1, virtual urgent care, and non-controlled refills with one provider
  • Cash-pay with a superbill option for out-of-network reimbursement
  • Founder Ahmed Emam is named in the footer

Where it loses points

  • Legal entity name not disclosed anywhere — can't be verified in a state registry
  • Pricing not shown before booking — you must enter the intake flow to see the fee
  • Pharmacy partner not named; model appears to fill at your preferred retail pharmacy
  • No medical director or prescribing clinician named — only 'board-certified providers'
  • No LegitScript badge, BBB profile, or HIPAA/SOC 2 seals displayed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard